- Home
- PAVM vs NRXS Comparison
PAVM vs NRXS Comparison
Compare PAVM & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- NRXS
- Stock Information
- Founded
- PAVM 2014
- NRXS 2011
- Country
- PAVM United States
- NRXS United States
- Employees
- PAVM N/A
- NRXS N/A
- Industry
- PAVM Medical/Dental Instruments
- NRXS
- Sector
- PAVM Health Care
- NRXS
- Exchange
- PAVM Nasdaq
- NRXS Nasdaq
- Market Cap
- PAVM 12.0M
- NRXS 13.0M
- IPO Year
- PAVM 2016
- NRXS 2023
- Fundamental
- Price
- PAVM $0.70
- NRXS $2.06
- Analyst Decision
- PAVM Strong Buy
- NRXS
- Analyst Count
- PAVM 1
- NRXS 0
- Target Price
- PAVM $19.50
- NRXS N/A
- AVG Volume (30 Days)
- PAVM 74.9K
- NRXS 37.7K
- Earning Date
- PAVM 05-15-2025
- NRXS 05-12-2025
- Dividend Yield
- PAVM N/A
- NRXS N/A
- EPS Growth
- PAVM N/A
- NRXS N/A
- EPS
- PAVM 0.50
- NRXS N/A
- Revenue
- PAVM $2,995,000.00
- NRXS $2,685,925.00
- Revenue This Year
- PAVM N/A
- NRXS $138,883.78
- Revenue Next Year
- PAVM $457.25
- NRXS $118.59
- P/E Ratio
- PAVM $1.39
- NRXS N/A
- Revenue Growth
- PAVM 22.14
- NRXS 9.18
- 52 Week Low
- PAVM $0.55
- NRXS $1.33
- 52 Week High
- PAVM $2.42
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- PAVM 47.02
- NRXS 52.30
- Support Level
- PAVM $0.70
- NRXS $1.94
- Resistance Level
- PAVM $0.80
- NRXS $2.40
- Average True Range (ATR)
- PAVM 0.06
- NRXS 0.30
- MACD
- PAVM -0.01
- NRXS 0.01
- Stochastic Oscillator
- PAVM 30.46
- NRXS 63.00
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).